OnCore Login

Return to Trial Database

QL12-153

Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153

Status

Study Completed

Cancer Type(s)

Quality of Life

Study Contact

Publications

Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy
  • MJ Brames, S Case-Eads, NH Hanna, CA Fausel , T Breen, LH Einhorn
Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy
  • C Albany, NH Hanna, J Picus, RJ Hauke, CA Fausel, Z Liu, MJ Brames, LH Einhorn
Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy
  • N Adra, C Albany, MJ Brames, S Case-Eads, CS Johnson, Z Liu, CA Fausel, T Breen, NH Hanna, RJ Hauke, J Picus, LH Einhorn

Trial Locations

All sites in which the trial QL12-153 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278